Milea Timbergen

211 Supplementary Table 5. (continued) Kim et al. 43 (2016), Oncology Letters Salas et al. 49 (2010), Genes, Chromosomes & Cancer Nishida et al. 42 (2016), Oncology Letters Mullen et al. 20 (2013), The Oncologist Mussi et al. 41 (2016), Tumori Broekhoven et al. 22 (2015), Annals of Surgical Oncology Colombo et al. 23 (2013), Cancer Recurrence Yes 67 (43%) 69 (36%) 1 (8%) 31 (27%) 3 (9%) 17 (17%) 48 (27%) No 90 (57%) 83 (43%) 12 (92%) 84 (73%) 30 (91%) 84 (84%) 131 (73%) Not applicable NS 23 (12%) NS NS NS NS NS Unknown 2 (1%) 19 (10%) NS NS NS NS NS Median/Mean follow-up in months [IQR]/(range) NS 58 (0.13-454) f 26 (6-63) f 31 g 42 (1-49) h 41 [18-71] i 50 [28-64] i Treatment k Wait and see NS NS NS NS NS NS NS Surgery 98 (62%) 125 (64%) 4 (31%) 105 (91%) 30 (91%) 56 (55%) 145 (81%) ST NS NS NS NS NS NS NS Surgery + (neo) A-ST 45 (28%) 20 (10%) 9 (69%) NS NS 5 (5%) 18 (10%) Rtx NS NS NS NS NS NS NS Surgery + Rtx (pre-or postoperative) 12 (8%) 21 (11%) NS 10 (9%) NS 40 (40%) 16 (9%) Surgery + (neo) A-ST + Rtx (pre- or postoperative) 4 (3%) NS NS NS NS NS NS Unknown NS 28 (14.4%) NS NS 3 (9%) NS NS 7